ALSUntangled # 69: astaxanthin

Authors

• Timothy Fullam, Department of Neurology, UTSA, San Antonio, TX, USA.
• Carmel Armon, Department of Neurology, Loma Linda University, Loma Linda, CA, USA.
• Paul Barkhaus, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA.
• Benjamin Barnes, Department of Neurology, Medical College of Georgia, Augusta, GA, USA.
• Morgan Beauchamp, Neurosciences Clinical Trials Unit, UNC Chapel Hill, NC, USA.
• Michael Benatar, Department of Neurology, University of Miami, Miami, FL, USA.
• Tulio Bertorini, Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USA.
• Robert Bowser, Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.Follow
• Mark Bromberg, Department of Neurology, University of Utah, Salt Lake City, UT, USA.
• Javier Mascias Cadavid, ALS Department, Hospital Carlos III-La Paz, Madrid, Spain.
• Gregory T. Carter, Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA.
• Mazen Dimachkie, Department of Neurology, University of Kansas, Kansas City, KS, USA.
• Dave Ennist, Origent Data Sciences, Inc, Vienna, VA, USA.
• Eva L. Feldman, Department of Neurology, University of Michigan, Ann Arbor, MI, USA.
• Terry Heiman-Patterson, Department of Neurology, Temple Health, Philadelphia, PA, USA.
• Sartaj Jhooty, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
• Isaac Lund, Green Hope High School, Cary, NC, USA.
• Christopher Mcdermott, Department of Neuroscience, University of Sheffield, Sheffield, UK.
• Gary Pattee, Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA.
• Dylan Ratner, Tulane University, New Orleans, LA, USA.
• Paul Wicks, Independent Consultant, Lichfield, UK, and.
• Richard Bedlack, Department of Neurology, Duke University, Durham, NC, USA.

Document Type

Article

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified "ALS reversal" occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

Keywords

Amyotrophic lateral sclerosis, alternative therapy, astaxanthin, neurodegeneration, oxidative stress

Publication Date

1-24-2023

Publication Title

Amyotrophic lateral sclerosis & frontotemporal degeneration

E-ISSN

2167-9223

First Page

1

Last Page

5

PubMed ID

36694292

Digital Object Identifier (DOI)

10.1080/21678421.2023.2171302

Recommended Citation

Fullam, Timothy; Armon, Carmel; Barkhaus, Paul; Barnes, Benjamin; Beauchamp, Morgan; Benatar, Michael; Bertorini, Tulio; Bowser, Robert; Bromberg, Mark; Mascias Cadavid, Javier; Carter, Gregory T.; Dimachkie, Mazen; Ennist, Dave; Feldman, Eva L.; Heiman-Patterson, Terry; Jhooty, Sartaj; Lund, Isaac; Mcdermott, Christopher; Pattee, Gary; Ratner, Dylan; Wicks, Paul; and Bedlack, Richard, "ALSUntangled # 69: astaxanthin" (2023). Translational Neuroscience. 2301.
https://scholar.barrowneuro.org/neurobiology/2301